SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Triple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC patients, this subtype still faces issues such as restricted treatment modalities, low pathological response rates, and unfavorable prognosis compared to other subtypes. Studies like Keynote522 and IMpassion031 have shown that combining chemotherapy with immunotherapy yields a pCR rate of 64.8% in early-stage high-risk TNBC patients, suggesting that such combinations can of

Trial Details

NCT ID
NCT06627712
Phase
PHASE3
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • SBRT+PD-1 Inhibitor + Chemotherapy
  • PD-1 Inhibitor + Chemotherapy
Locations (sample)
  • Sichuan, Chengdu, China|35.1221,105.48032

Key Eligibility Criteria

  • 1\. Histologically or cytologically confirmed TNBC (ER-, PR-, HER2-)
  • 2\. cT1cN1-2M0 or cT2N0-2M0；（AJCC 7th）
  • 3\. ECOG performance status of 0-1;
  • 4\. Adequate bone marrow function, defined as: Hb ≥ 9.0 g/dL (90 g/L); ANC ≥ 1,500/mcL (1.5 × 10\^9/L); PLT ≥ 100,000/mcL (100 × 10\^9/L) and no bl…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →